Literature DB >> 7503602

Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases.

S M Arend1, F P Kroon, J W van't Wout.   

Abstract

BACKGROUND: Pneumocystis carinii pneumonia (PCP) occurs in immunocompromised patients without the acquired immunodeficiency syndrome (AIDS). There has been an increasing yearly number of cases of PCP in our patients without AIDS.
OBJECTIVE: To determine the nature of the underlying disorder and previous immunosuppressive treatment in patients with PCP without AIDS.
METHOD: A study of the charts of 78 such patients admitted to our hospital from 1980 through 1993.
RESULTS: The number of PCP cases per year increased during the period studied. All patients had an underlying disorder, either hematologic malignancy (49%), solid organ tumor (4%), vasculitis or other immunologic disorder (22%), or they had undergone renal transplantation (17%) or bone marrow transplantation (9%). Previous immunosuppressive medication consisted of prednisone or other corticosteroids in 72 (92%) of 78 patients, cytotoxic drugs in 55 (71%) of 78 patients, both in 50 (64%) of 78 patients, and none in one patient. Quantification of previous corticosteroid treatment showed a large variability among patients. The overall mortality rate for patients was 35% (27/78). Mortality was significantly higher in patients with a concomitant pulmonary infection (P = .01), an underlying disorder other than that which resulted in renal transplantation (P = .03), mechanical ventilation (P < .001), previous chemotherapy (P = .04), as well as previous cyclophosphamide treatment (P = .01). A trend toward a higher mortality in patients with previous corticosteroid use was detected (P = .06).
CONCLUSION: Pneumocystis carinii pneumonia may complicate a variety of immunocompromised states, with considerable mortality. Pneumocystis carinii pneumonia occurred at all levels of immunosuppression; no threshold level could be defined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7503602

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  36 in total

1.  Lymphocyte surge as a marker for immunorestitution disease due to Pneumocystis jiroveci pneumonia in HIV-negative immunosuppressed hosts.

Authors:  V C C Cheng; I F N Hung; A K L Wu; B S F Tang; C M Chu; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-13       Impact factor: 3.267

2.  Pneumocystis carinii pneumonia in HIV-negative patients with haematologic disease.

Authors:  J van der Lelie; D Venema; E J Kuijper; R P van Steenwijk; M H van Oers; L L Thomas; A E von dem Borne
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

3.  Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.

Authors:  Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

4.  Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem?

Authors:  Omer Omer; Patrizia Cohen; Shuet Fong Neong; Geoffrey V Smith
Journal:  Frontline Gastroenterol       Date:  2014-09-22

5.  Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii carriage in renal transplantation patients: a single-centre experience.

Authors:  Matthias Maruschke; Diana Riebold; Martha Charlotte Holtfreter; Martina Sombetzki; Steffen Mitzner; Micha Loebermann; Emil Christian Reisinger; Oliver W Hakenberg
Journal:  Wien Klin Wochenschr       Date:  2014-09-19       Impact factor: 1.704

Review 6.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases.

Authors:  Yoko Aoki; Masahiro Iwamoto; Yasuyuki Kamata; Takao Nagashima; Taku Yoshio; Hitoaki Okazaki; Seiji Minota
Journal:  Rheumatol Int       Date:  2009-01-14       Impact factor: 2.631

8.  Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.

Authors:  Ratchaya Lertnawapan; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

9.  Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy.

Authors:  Sadhna M Shankar; Joseph J Nania
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

10.  Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis.

Authors:  James C Lee; Deborah C Bell; Richard M Guinness; Tariq Ahmad
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.